This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
ESC 2022: Risk Score Predicts Mortality for AF Patients after TAVI
In the past, there has not been an accurate way to calculate mortality risk for patients with atrial fibrillation (AF) who have undergone a successful transcatheter aortic valve implantation (TAVI) and have been discharged home. Now, researchers with the ENVISAGE-TAVI AF trial have developed a risk score to more accurately predict mortality in TAVI patients. George Dangas, of The Zena and Michael A. Wiener Cardiovascular Institute, presented the trial’s findings at the European Society of Cardiology Congress 2022, highlighting that the new risk assessment score focuses on improving outcomes by determining how to categorize patients after a successful TAVI and discharge. Dangas added that the analysis will continue to enhance the understanding of patient risk after TAVI.